Beyond cold plunges: the real longevity breakthrough

Dr. Hillary Lin's Longevity Takes

The Long Game

​

Hi {{ subscriber.first_name | strip | default: "there" }},

Quick note before I head off to watch the Super Bowl (Go Birds!). While everyone's eyes are on the big game, I've also been focused on some game-changing developments in medicine...

The kind that could transform how we treat cancer.

Quick hit before you dive in: We're entering an era where a single injection could eliminate tumors completely. Not in some distant future – it's happening now. This isn't just another incremental advance in cancer treatment; it's a fundamental reimagining of what's possible.

This piece explores why we need to think bigger when it comes to longevity. Beyond the basics, the real future lies in precision medicine that targets disease at its source.

Dive in below. 🦅

A Paradigm Shift in the Cancer Landscape

Precision Medicine and the Promise of Breakthroughs

Cancer. Just hearing the word can spark a sense of dread. Families across generations know how devastating it can be—especially when it comes to breast cancer, which often requires a physically and emotionally taxing journey through surgery, radiation, and hormone therapy. Yet a remarkable transformation in treatment is taking shape.

We stand at the edge of a new era: precision medicine. Picture a single, targeted injection that can eradicate advanced tumors. Or a personalized vaccine that teaches the immune system to recognize and destroy the unique mutations within one patient’s cancer. This is no longer science fiction. These near “magic bullets” are fast becoming reality in the evolving world of modern oncology.

The Breakthrough of ErSO-TFPy for Breast Cancer

One breakthrough capturing attention is ErSO-TFPy, a novel compound studied at the University of Illinois. In preclinical work with mice, a single dose of this drug—related to a compound previously shown to shrink tumors—was enough to eradicate small estrogen receptor-positive (ER+) breast cancer tumors and significantly shrink larger ones. This single-injection approach marks a bold departure from the typical, multi-pronged regimens of conventional cancer care.

This news captured my imagination for what the future might bring. I spent years practicing oncology before shifting my focus to longevity medicine. Cancer looms large in my own family history, and recent genetic testing suggests I may face an increased risk for several cancer types. So, when I see the promise of ErSO-TFPy, I recognize more than a scientific advance. I see a turning point that could redefine cancer treatment from incremental improvements to a fundamental leap forward.

​Read More.​

Thanks so much for reading!

You can stay updated by following me everywhere @hillarylinmd

Join Livora's Longevity Programs here.​

Hillary Lin, MD is a Stanford MD and Board Certified Internal Medicine Physician. Dr. Lin practices healthspan- and longevity-focused medicine at Livora Health, her private concierge telemedical practice. Keep in touch to hear about our upcoming, exciting projects in longevity health!

​​​​

www.hillarylinmd.com

The information provided in this newsletter is intended solely for general educational purposes and is not meant to be, nor should it be construed as, personalized medical advice. No doctor-patient relationship is established by your use of this or any other content platform with Hillary Lin, MD.

Was this email forwarded to you? Sign up here.​
​Unsubscribe · Preferences​

​